Covance Blog - Sharing Innovation in Drug Development
    • Effectively Managing Investigators and Sites in Inflammation Clinical Trials

      Posted by
      Published On Oct 27 2015, 3:40 AM

      (This is part 2 of a 3-part series on Inflammatory Disorders Studies. View part 1 here.View the complete series in our Inflammation eBook.

      Ensure your ROI and keep  inflammation clinical trials on track.

      The good news: The surge in the number and size of industry-sponsored trials in Covance Inflammation Bloginflammation presents opportunity. The not-so-good news: The surge also presents challenge. Clinical trials for Immune-Mediated Inflammatory Disorders (IMIDs) present certain pressures for even the most committed investigators and sites: IMID trials frequently have longer than usual duration and enrollment can be highly competitive. Additionally, patients whose disease is well-managed by the new treatments available may not be motivated to try something different.

      To have investigators who are able to deliver approvable data enrolled on a timely basis, action should be taken to attract and retain investigators through a variety of measures. These include:

      • Protocol simplicity
      • Reasonable sample size requirements
      • Competitive investigator remuneration paid promptly
      • Thought leader engagement and professional meeting presentations

      To ensure a timely, effective IMID clinical trial, at the most basic level, sites must perform and meet targets. Non-performing and under-performing sites will generate unnecessary delays and waste resources for all concerned stakeholders.

      With your CRO, you can take the following steps:

      • Have an escalation plan in place for non/under-performing sites that facilitates close-out if warranted
      • Recruit more sites than needed and bring them through regulatory approval, holding their activation until needed. Usually failing sites are identified within three months of activation and standby sites can be readily deployed to fill the gap without compromising time or quality
      • Be able to draw on a knowledge base that enables site, investigator and geographic selection to meet study needs for patient enrollment

      Although, IMID studies present challenges, identifying these challenges beforehand and proactively addressing them can protect your objectives, investments and resources.

      Visit our website for more information on inflammation drug development.

      Download our Inflammation eBook. 

    This entry was posted in Clinical Testing and tagged , , by Bookmark the permalink

    About Joan Meyer, Ph.D.

    Joan Meyer, Ph.D., is the Operational Strategy & Planning Global Therapeutic Area Head for Inflammation, Infectious Diseases, and General Medicine at Covance. Dr. Meyer has more than 25 years of pharmaceutical and CRO experience, holding leadership positions in project management, strategic marketing, and study start-up. She has also served in leadership roles in the Ohio River Valley and National Arthritis Foundations. Dr. Meyer graduated from St. Mary s University, Minnesota, with a BA in Biology and BA in Psychology. She received her Master of Science and Ph.D. in Neuroscience from the University of Illinois at Urbana-Champaign, where she taught in the College of Medicine.